ArtivionAORT
AORT
About: Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
Employees: 1,600
0
Funds holding %
of 7,431 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
11,200% more call options, than puts
Call options by funds: $678K | Put options by funds: $6K
26% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 23
25% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 56
25% more capital invested
Capital invested by funds: $1.04B [Q1] → $1.3B (+$257M) [Q2]
2% more funds holding
Funds holding: 183 [Q1] → 186 (+3) [Q2]
0.11% less ownership
Funds ownership: 97.6% [Q1] → 97.49% (-0.11%) [Q2]
25% less funds holding in top 10
Funds holding in top 10: 4 [Q1] → 3 (-1) [Q2]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$39
11%
downside
Avg. target
$42
3%
downside
High target
$50
15%
upside
5 analyst ratings
4 positive
80%
1 neutral
20%
0 negative
0%
Needham Mike Matson | 15%upside $50 | Buy Maintained | 22 Aug 2025 |
Ladenburg Thalmann Jeff Cohen | 11%downside $39 | Neutral Downgraded | 13 Aug 2025 |
Canaccord Genuity William Plovanic | 6%downside $41 | Buy Maintained | 8 Aug 2025 |
JMP Securities Daniel Stauder | 4%downside $42 | Market Outperform Maintained | 8 Aug 2025 |
Stifel Rick Wise | 8%downside $40 | Buy Maintained | 8 Aug 2025 |
Financial journalist opinion
Based on 5 articles about AORT published over the past 30 days
Neutral
Seeking Alpha
2 weeks ago
Artivion, Inc. (AORT) Q2 2025 Earnings Call Transcript
Artivion, Inc. (NYSE:AORT ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Lance A. Berry - Executive VP of Finance & CFO Pat MacKin - Corporate Participant Conference Call Participants Daniel Walker Stauder - Citizens JMP Securities, LLC, Research Division Destiny Alexandra Hance Buch - Ladenburg Thalmann & Co. Inc., Research Division John Glenn McAulay - Stifel, Nicolaus & Company, Incorporated, Research Division William John Plovanic - Canaccord Genuity Corp., Research Division Dorothy Morgan - Gilmartin Group LLC Operator Good day, ladies and gentlemen, and welcome to the Artivion Second Quarter 2025 Earnings Call.
Positive
Zacks Investment Research
2 weeks ago
Artivion (AORT) Tops Q2 Earnings and Revenue Estimates
Artivion (AORT) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.07 per share a year ago.
Positive
The Motley Fool
2 weeks ago
Artivion (AORT) Q2 EPS Jumps 243%
Artivion (AORT) Q2 EPS Jumps 243%
Neutral
PRNewsWire
2 weeks ago
Artivion Reports Second Quarter 2025 Financial Results
Second Quarter Highlights: Achieved revenue of $113.0 million in the second quarter of 2025 versus $98.0 million in the second quarter of 2024, an increase of 15% on a GAAP basis and 14% on a non-GAAP constant currency basis Net income was $1.3 million, or $0.03 per fully diluted share and non-GAAP net income was $10.7 million, or $0.24 per fully diluted share in the second quarter of 2025 Adjusted EBITDA increased 33% to $24.8 million in the second quarter of 2025 compared to $18.6 million in the second quarter of 2024 Exchanged $99.5 million in principal amount of outstanding convertible senior notes due July 1, 2025 for common stock, resulting in the effective retirement of previously issued notes Received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to initiate the ARTIZEN pivotal trial evaluating the efficacy and safety of Arcevo LSA to replace the entire aortic arch for the treatment of acute and chronic arch pathologies ATLANTA , Aug. 7, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the second quarter ended June 30, 2025. "The second quarter was exceptionally strong as we made progress across each of our strategic initiatives while delivering 14% constant currency revenue growth.
Neutral
PRNewsWire
3 weeks ago
Artivion to Participate in Upcoming Investor Conferences
ATLANTA , July 30, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences. Artivion's management team will present at the upcoming Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025 at the InterContinental Boston Hotel.
Neutral
PRNewsWire
1 month ago
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2025 Financial Results
ATLANTA , July 24, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2025 financial results will be released on Thursday, August 7, 2025, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.
Neutral
GlobeNewsWire
1 month ago
DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of Artivion, Inc. Customers Whose Data May Have Been Compromised
NEWTOWN, Pa., July 13, 2025 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP is investigating data privacy claims regarding an incident at Artivion, Inc. (“Artivion”).
Neutral
PRNewsWire
2 months ago
Artivion to Participate in Upcoming Investor Conferences
ATLANTA , June 3, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investors conferences. Artivion's management team will present at the upcoming Truist Securities MedTech Conference on Tuesday, June 17, 2025, at the InterContinental Boston Hotel.
Neutral
PRNewsWire
2 months ago
Artivion Announces Closing of Transactions to Exchange $99.5 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock
ATLANTA , May 28, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the closing of transactions related to previously announced, privately negotiated exchange agreements with certain holders (the "Holders") of its 4.250% Convertible Senior Notes due 2025 (the "Notes"). The closing transactions included the closing of an additional, privately negotiated agreement with a separate holder.
Neutral
PRNewsWire
3 months ago
Artivion Announces Agreements to Exchange $95 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock
ATLANTA , May 14, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it entered into separate, privately negotiated exchange agreements with certain holders of its 4.250% Convertible Senior Notes due 2025 (the "Existing Convertible Notes"). Under the exchange agreements, the company will, subject to customary closing conditions, repurchase approximately $95 million principal amount of Existing Convertible Notes in exchange for a number of shares of the company's common stock to be determined based on the trading price of the common stock over a four trading day averaging period beginning on May 15, 2025 (the "Shares").
Charts implemented using Lightweight Charts™